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Abstract
Background: Although circulating levels of sexual hormones in elderly men and women are low and quite similar,
the adaptation of the elderly heart to stress differs between the sexes. We have hypothesized that the effects of
sexual hormones in the heart may differ in men and women. Here, we assessed whether 17b-oestradiol regulates
gene expression in the human heart in a sex-dependent manner. We selected the progesterone receptor as a well
studied 17b-oestradiol target that may be pathologically linked to cardiac remodelling.
Methods: In order to assess the ex vivo effects of 17b-oestradiol in intact human cardiac tissues, we developed a
24-h model for the culture of human atrial myocardium. We verified tissue viability after 24 h in culture with two
standard assays to determine the degree of apoptosis and metabolic activity of cardiac tissues. Progesterone
receptor mRNA and protein level were measured after 24-h treatment of tissues with 17b-oestradiol. Statistical
analysis was performed by the Mann-Whitney U test and two-way ANOVA.
Results: We established a tissue culture model that allows for the study of viable human cardiac tissue over a 24-h
period. After 24 h, cultured cardiac tissues revealed low apoptosis, retained their metabolic activity and, therefore,
remained viable. Treatment with 17b-oestradiol led to an induction of the progesterone receptor mRNA level in
female (P = 0.001) but not in male tissues. Similarly, there was an increase in the level of progesterone receptor
protein in female tissues (P = 0.03), while a decreasing trend was observed in male tissues (P = 0.079) exposed to
17b-oestradiol.
Conclusions: Our novel finding may offer a molecular explanation for the sex-specific differences observed in
cardiac remodelling. The culture model we established for human cardiac tissue will facilitate the study of cellular
processes in health and disease and will be of use for pharmacological testing.
Background
Human and animal studies have demonstrated sex-
specific differences in cardiac remodelling, where
females have a better outcome than males. However, the
molecular mechanisms resulting in males undergoing
more severe remodelling than females are poorly under-
stood. In the hypertrophic response, cardiac remodelling
occurs as a result of abnormal fibroblast proliferation,
which leads to fibrosis. The steroid hormone 17b-
oestradiol (E2) is largely considered to contribute signifi-
cantly to the manifestation of sex-specific differences.
Indeed, multiple effects for E2 on the cardiovascular sys-
tem have been reported [1]. Along this line, E2 is
expected to limit fibrotic remodelling [2,3] mediated by
less well described mechanisms.
E2 regulates a large number of genes, including pro-
gesterone receptor (PGR). The PGR protein belongs to
the superfamily of ligand-activated transcription factors
that regulate gene expression and mediates the genomic
and non-genomic actions of progestins. It is expressed
and functionally active in a number of different cell
types, including vascular smooth muscle cells [4],
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[7]. To date, E2 has been shown to regulate the PGR
gene in a sex-dependent fashion in specific brain regions
of adult rats [8] and in human lung adenocarcinoma cell
lines [9].
The study of the effects exerted by E2 directly on cells
of the heart is crucial. Nevertheless, although conven-
tional two-dimensional cell culture models have been
extremely useful for studying extra- and intra-cellular
physiology, some hypotheses do not lend themselves to
two-dimensional models [10]. For instance, the microen-
vironment that defines the niche, a dynamic architecture
with anatomic and functional dimensions [11], may not
be realized in conventional cell culture systems. Further-
more, tissues are made up of more than a single cell type
and the interaction of cells drives their response to sti-
muli. As a result, hormones may exert a different effect
on the same cell type at a tissue or organ level in compar-
ison to a cell culture system [12]. Generally, such systems
also lack the influence of a normal extracellular matrix
(ECM) and even less that of an abnormal ECM, as occurs
in target-organ damage such as interstitial fibrosis in the
heart which contributes to cardiac remodelling.
To date, due to obvious hurdles, there have been no
reports of long-term gene and protein expression studies
addressing the direct effects of stimuli and investigating
the underlying molecular mechanisms of physiological
and pathological cellular processes in the heart of
humans. Murine embryonic heart slices [13] and iso-
lated mammalian papillary muscle strips [14,15] have
only allowed the measurement of the development of
mechanical force in a narrow temporal space. Isolated
myocardial strips have also been used for a short stimu-
lation period [16], thus making longer-term molecular
studies of biological processes difficult and resulting in
imperfectly defined viability.
In the present study, we describe an ex vivo tissue cul-
ture system which maintains healthy human cardiac tis-
sues in culture for up to 24 h. We assured viability of
the cultured tissues under defined conditions. Subse-
quently, we applied this model to treat cardiac tissues
with E2. We provide the first evidence that E2 induces
the expression of the PGR messenger RNA (mRNA) and
p r o t e i ni nt h eh e a r tt i s s u e so fw o m e nb u tn o ti nt h o s e
of men. This finding contributes to a molecular explana-
tion for the sex-specific differences observed in the
diverse remodelling responses in men and women and
in animal studies after myocardial infarction. It could
also have major implications for hormone therapy.
Methods
Patients and tissue harvest
All chemicals and reagents were purchased with highest
purity grade available from Sigma-Aldrich (MS, USA)
unless otherwise indicated. The study was approved by
the Charite Medical University Berlin Ethics Committee
and complies with the principles outlined in the
Declaration of Helsinki. Written consent from patients
undergoing coronary bypass surgery was obtained for
use of their tissue from the right atrium, ensuring that
t h et i s s u es a m p l ec o l l e c t ion would originate from a
healthy part of the heart. Tissues were collected from 15
men and six women for the whole study and subsets of
these were used for different assays. There were no sig-
nificant differences in the medication between males
and females and their baseline characteristics are shown
in Table 1. A piece of the appendage of the right atrium
m e a s u r i n ga b o u t1 0m ml o n gw a se x c i s e dj u s tb e f o r e
cardiopulmonary bypass. Tissues were quickly trans-
ported from the operating room to the laboratory in
cold Krebs Henseleit buffer (KHB) (120 mM NaCl,
5m MK C l ,2m MM g S O 4,1 . 2m MN a H 2PO4,2 0m M
NaHCO3, 10 mM glucose, 0.25 mM CaCl2, pH 7.4).
Tissue culture and tissue treatment
Upon tissue removal and immediate incubation in cold
KHB, all tissues were processed within 20 min. Prior to
collecting the tissue, the KHB was freshly oxygenated
with carbogen gas (95% O2,5 %C O 2)f o r1ha tas p e e d
of 0.5 L/min achieving an O2 pressure of 247.9 ± 8.3
mm Hg on average (Rapidlab 865; Bayer Diagnostics/
Chiron Diagnostics, Leverkusen, Germany). The col-
lected tissue was examined macroscopically and any fat
detected was removed. The tissue was cut further into
uniformly smaller pieces about 3-5 mm long each
depending on the size of the initial sample. Then, each
smaller piece was transferred to a 50 mL Falcon tube
containing a modified KHB supplemented with 20 mM
2,3-butanedione monoxime and 10
-8 M2 - h y d r o x y p r o -
pyl-b-cyclodextrin (HBC)-encapsulated E2 or 10
-8 M
HBC (control for E2 treatment) and was incubated at
37°C in a conventional water bath for 24 h. This con-
centration was chosen to obtain an E2 level of physiolo-
gical range. Following the completion of the treatment,
the tissues were shock frozen in liquid nitrogen and
stored at -80°C until further analysis. For the purpose of
testing the viability of the tissues, the following groups
with three tissues from three individuals each were
investigated: fresh (control for viability; shock frozen in
Table 1 Characteristics of the individuals whose tissues
were employed in the study
Men (n = 15) Women (n =6 )
Age (years) (mean ± SD) 65.07 ± 6.43 76.00 ± 3.74
BMI (kg/m
2) (mean ± SD) 27.47 ± 3.26 23.50 ± 3.35
EF (%) (mean ± SD) 59.80 ± 5.99 54.33 ± 8.81
BMI, body mass index; EF, ejection fraction; SD, standard deviation.
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immediately after cutting), damaged (control for death;
incubated in distilled water at room temperature for 24
h), E2-treated (cultured and treated with E2 for 24 h)
and HBC-treated (control for E2-treatment; cultured
and treated with HBC for 24 h).
Terminal deoxynucleotidyl transferase (TdT) assay
A common method for the detection of apoptosis was
applied in order to establish the degree of cell death in
the different tissue groups. The Fluorescein Fragel™
DNA Fragmentation Detection Kit (Calbiochem; VWR,
Darmstadt, Germany,) was used according to the man-
ufacturer’s instructions in 5-μm-thick slices from the
core of frozen tissues embedded in Neg-50 frozen sec-
tion medium (Thermo Scientific, Richard-Allan Scien-
tific, MI, USA). Total and apoptotic nuclei were
determined by a fluorescence microscope (Leica
DMIREZ; Leica Microsystems, Wetzlar, Germany)
using a Retiga 1300 camera (Q Imaging) and Openlab
version 5.5.0 (Improvision). To calculate the apoptotic
index, five images of different areas of a tissue section
covering most of the section were taken from three
independent tissues for each group. Total and apopto-
tic nuclei were counted and the number of apoptotic
nuclei was divided by the total number of all nuclei in
each of the five images. Then, the mean of these for
each section were taken.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
In order to assess the metabolic activity of the cells, we
used a modified colorimetric MTT assay. This assay is
based on the enzymatic activity of the mitochondrial
dehydrogenase, which converts the soluble yellow MTT
salt into insoluble purple formazan crystals by cleaving
the tetrazolium ring [17]. Tissues were incubated in
1 mL KHB supplemented with 100 μLM T Ts o l u t i o n
[5 mg/mL in phosphate buffered saline (PBS)] at 37°C
for 3 h. Following incubation, tissues were either frozen
in liquid nitrogen or incubated in 400 μLl y s i sb u f f e r
(99.4 mL DMSO, 0.6 ml acetic acid glacial 100%, and 10
g sodium dodecyl sulphate) at 4°C overnight in order to
dissolve the formazan crystals formed within the cells.
Then, 100 μL of the lysed solution were transferred to a
96-well plate and the absorbance was measured at 570
nm on a microtitre plate spectrophotometer (Bench-
mark Plus; Bio-Rad, CA, USA). In order to examine for-
mazan formation following MTT exposure, frozen
tissues were embedded in Neg-50 frozen section med-
ium and serial cross-sectioned. Five micrometre thick
slices from the tissue core were mounted on slides and
were examined microscopically (Leica DMIREZ; Leica
Microsystems). Images were taken using a Retiga 1300
camera (Q Imaging) and Openlab version 5.5.0
(Improvision).
Gene expression study
Total RNA was isolated from nine male and four female
frozen tissues using the Rneasy Fibrous Tissue Mini kit
(Qiagen, Hilden, Germany) following the manufacturer’s
protocol. The RNA quality and quantity was established
using a 2100 Bioanalyzer (Agilent Technologies, CA,
USA). Then, 0.5 μg of total RNA was reverse tran-
scribed into cDNA using the High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems, CA,
USA) according to the manufacturer’s instructions.
Quantitative real-time RT-PCR reactions were per-
formed in 25 μL final volume using SYBR Green
(Applied Biosystems) in a 7000 ABI Prism Instrument
(Applied Biosystems). Reactions where RNA or reverse
transcriptase had previously been omitted during reverse
transcription were used as negative controls. In order to
normalize cDNA concentration in different samples, the
expression of pyruvate dehydrogenase (lipoamide) beta
(PDHB), hypoxanthine phosphoribosyltransferase 1
(HPRT1) and ribosomal protein large P0 (RPLP0)w a s
measured and a normalization factor from the mean of
their expression levels was calculated, by which the
quantity of PGR was divided. The sequences of the pri-
mer pairs used and the size of the products are: HPRT1:
5’-CTTTGCTGACCTGCTGGATT-3’ and 5’-TATGT-
CCCCTGTTGACTGGT-3’, 121 bp; PDHB:5 ’-GGTAT-
GGATGAGGAGCTGGA-3’ and 5’-CTTCCACAGC-
CCTCGACTAA-3’, 102 bp; PGR:5 ’-TCCTTACCTGT-
GGGAGCTGT-3’ and 5’-CGATGCAGTCATTTCTT-
CCA-3’,9 0b p ;a n dRPLP0:5 ’-ACGGGTACAAAC-
GAGTCCTG-3’ and 5’-AGCCACAAAGGCAGATG-
GAT-3’, 104 bp.
Protein abundance analysis
Four male and four female tissues were homogenized in
a detergent-containing lysis buffer with protease inhibi-
tor. Per lane, 7.5 μg protein were loaded on 6% SDS-
PAGE gels and transferred to nitrocellulose membranes.
Antibodies against PGR (Cell Signaling) and actin (Santa
Cruz, CA, USA; loading control) were used. Immunor-
eactive proteins were detected using the ECL Plus (GE
Healthcare, Buckinghamshire, UK) and quantified by the
ImageJ 1.41 version software.
Statistical analysis
All experiments were performed with three or more
independent tissue samples. Each tissue originated from
a different individual. Data are shown as the mean ±
standard deviation. All data were analyzed statistically
using the R version 2.8.0 software. For the apoptotic
(TdT) and the biochemical (MTT) assays, statistical
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one-tailed Mann-Whitney U test. For the gene and pro-
tein expression studies, normality of the data was evalu-
ated by means of the Shapiro-Wilk test. Statistical
analysis was performed using two-way ANOVA. All
pairs of means were compared by Tukey’s post hoc test
adjusting for multiple comparisons. A value of P ≤ 0.05
was considered statistically significant.
Results
Level of apoptosis in cultured tissues
Programmed cell death was assessed with the TdT
assay. In apoptosis, TdT can detect the DNA double-
strand breaks with single base 3’ overhangs by binding
to exposed 3’-OH ends of DNA fragments. Apoptotic
nuclei were identified in situ in the four groups investi-
gated: fresh (control for viability), damaged (control for
death), E2-treated and HBC-treated (control for E2
treatment; Figure 1A). In order to semi-quantify the
TdT-positive nuclei, the apoptotic index in tissues from
each group was calculated. Few apoptotic nuclei were
found in E2- and HBC-treated tissues similar to fresh
tissues, while damaged tissues showed an extensive level
of apoptosis (P = 0.05 for damaged versus E2- and
HBC-treated and fresh; Figure 1A and 1B).
Metabolic activity of cultured tissues
The MTT assay assesses the metabolic activity of cells
and is a well-established method for determining cell
viability. In viable and metabolically active cells, the
mitochondrial dehydrogenase enzyme converts the solu-
ble yellow MTT salt into insoluble purple formazan
crystals. Determination of in situ formazan crystal for-
mation in the different groups under investigation
revealed that crystals formed both in fresh and E2-
treated tissues but not in the group of damaged tissues
(Figure 2A). Quantification of the metabolic activity
c o n f i r m e dt h a tf r e s ha n dE 2 - t r e a t e dt i s s u e sh a dv e r y
similar amounts of crystals while damaged tissues
showed much lower crystal levels (P = 0.05 for damaged
vs. E2-treated and fresh; Figure 2B). Therefore, E2-
treated tissues retain their metabolic activity and remain
viable, as demonstrated by the formation of formazan
crystals.
Sex-specific PGR regulation by E2
Due to interests in hormonal effects and for the valida-
tion of the tissue culture system, human cardiac tissues
were treated with E2 and the expression level of PGR,a
known E2-target gene, was assessed by quantitative RT-
PCR. It was discovered that the PGR mRNA level was
modulated by E2 in a sex-specific manner as determined
by analysis of variance (n = 13, interaction P <0 . 0 0 1 ) .
Post-hoc analysis confirmed that following a 24-h
E2-treatment the mRNA level of PGR displayed a
1.36-fold significant increase in tissues of female indivi-
duals (n = 4, adjusted P = 0.001; Figure 3A). However,
E2-exposure had no effect on the PGR expression level in
tissues from male individuals (n = 9, adjusted P =0 . 9 ;
Figure 3B).
Subsequently, the abundance level of the PGR protein
in cardiac tissues treated with E2 was investigated. Of
great importance, it was discovered that the PGR pro-
tein follows the same expression pattern as the PGR
gene after E2-exposure showing a sex-specific regulation
(n = 8, interaction P = 0.0028). In particular, tissues of
female individuals treated with E2 exhibited a 1.40-fold
increase in the protein level of PGR (n = 4, adjusted P =
0.03; Figure 3C), while E2-treated tissues of male indivi-
duals revealed a decreasing trend for PGR (n =4 ,
adjusted P = 0.079; Figure 3D).
Discussion
Our novel finding is that, with the aid of a robust sys-
tem for the culture of intact human heart tissue, we
showed that in response to E2, cardiac tissues from
women increase PGR mRNA expression and protein
level, while cardiac tissues from men do not. We believe
this report is the first demonstrating that E2 acts in the
heart in a sex-specific manner. A modified KHB was
used to maintain whole cardiac tissue viability. KHB
with no further supplements has generally been used for
the transport of explanted hearts [18,19] and for the
short stimulation of myocardial strips [16] but not for
the culture of tissues. Furthermore, freshly oxygenated
buffer with known oxygen pressure was used, as uncon-
trolled oxygenation might lead to artifacts. An approxi-
mately 2-3 mm tissue thickness enabled oxygenation of
the tissues by diffusion.
Moreover, two standard and well-received assays were
recruited to assess the viability and the metabolic activ-
ity of the tissues. The TdT assay demonstrated extensive
apoptosis in the group of damaged tissues (Figure 1A
and 1B). The very few apoptotic nuclei observed in E2-
and HBC-treated and in fresh tissues were expected, as
some cell death would occur (Figure 1A and 1B). Simi-
l a r l y ,t h eM T Ta s s a yr e v e a led a maintained metabolic
activity of the E2-treated tissues compared to fresh tis-
sues used as positive controls for viability (Figure 2A
and 2B). On the other hand, the negative controls
( d a m a g e dt i s s u e s )s h o w e dv ery low levels of metabolic
activity (Figure 2A and 2B). Both the TdT and MTT
assays indicate that the current system maintains the
human cardiac tissues in culture viable for at least 24 h.
When validating the system, it was found that the
expression level of the PGR mRNA increases in the
female human myocardium but does not change in the
male human myocardium following E2 treatment
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Page 4 of 9Figure 1 Degree of apoptosis in cultured tissues. (A) Representative images of 5 μm-thick tissue sections labelled with terminal
deoxynucleotdyl transferase (TdT). Few apoptotic nuclei are present in E2- and 2-hydroxypropyl-b-cyclodextrin (HBC)-treated and fresh tissues,
while large numbers of apoptotic-positive nuclei are observed in damaged tissues. Fresh: control for viability; damaged: control for death; HBC-
treated: control for E2 treatment. TdT (green) indicates apoptotic nuclei. Merged images with DAPI are shown in right panels. Scale bar, 100 μm.
(B) The apoptotic index is low in E2- and HBC-treated and fresh tissues but significantly higher in damaged tissues (n =3 ,* P = 0.05 for
damaged versus E2- and HBC-treated and fresh). Data represent means ± standard deviation.
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PGR expression was expected, as small fold changes due
to E2 treatment have been previously reported [20,21].
More importantly, a similar increase was identified at
the protein level of PGR (Figure 3C and 3D). In addi-
tion, the heart is a strictly-regulated environment, where
it is expected that minor changes have major effects.
Indeed, the effects of progestins vary greatly and are tis-
sue dependent. Both progesterone and its receptor are
necessary for successful pregnancy and birth [22-24]. In
observational studies, progesterone acts in a vasocon-
strictive way [25-28], while it exerts vasorelaxation
effects on vascular tissue in vitro [29]. In animal studies,
progestins have been reported to reverse the atheropro-
tective effects of E2 [30-33]. Additionally, molecular stu-
dies have shown progesterone to regulate transcription
in vascular endothelial cells and in vascular smooth
muscle cells, where it inhibits proliferation through the
modification of cyclin E and A transcription, which in
turn leads to arrest in the G0-G1 stage [4,5,34,35].
Although, the regulation of PGR by E2 in several cell
types has been well documented and the sex-specific
manner of this has been described in the brain [8] and
in human lung adenocarcinoma cell lines [9], to our
knowledge, how E2 might affect the PGR gene and pro-
tein levels in the heart has not been previously reported.
Furthermore, the mechanism responsible for this sex-
specific regulation currently is not well understood.
However, we believe that the recruitment of different
cofactors to the ligand-receptor complex at the promo-
ter region of PGR between the two sexes might be a
crucial step. In addition, it has to be mentioned that the
exact cellular type, where this regulation occurs, has not
been identified. Nevertheless, in future studies this issue
needs to be addressed.
The protective effects of E2 on the cardiovascular sys-
tem have long been recognized and several biochemical
pathways by which E2 could exert such effects have
been described [1]. We propose further insight into how
E2 might protect against cardiac remodelling. The pro-
liferation of cardiac fibroblasts contributes to pathologi-
cal structural changes in the heart [36]. E2 inhibits
cardiac fibroblast growth [36]. Furthermore, in addition
to the anti-proliferative effects of progesterone on vascu-
lar cells discussed above, progesterone inhibits DNA
synthesis in neonatal cardiac fibroblasts [6], cardiac
Figure 2 Metabolic activity of cultured tissues. (A) Representative images of 5 μm-thick tissue sections incubated in MTT. Fresh and E2-
treated tissues display formazan crystal formation affirming tissue viability, while no crystals formed in damaged tissues. Scale bar, 50 μm. (B)
Amount of dissolved formazan crystals measured in a spectrophotometer. In fresh and E2-treated tissues there are equally high amounts of
crystals as determined by the absorbance measured, while in damaged tissues the crystal levels are significantly lower (n =3 ,* P = 0.05 for
damaged versus E2-treated and fresh). Data represent means ± standard deviation.
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E2 [36]. Thus, it has been suggested that hormone ther-
apy using E2 and progesterone may protect postmeno-
pausal women against cardiovascular disease by
inhibiting cardiac fibroblast growth and cardiac remo-
delling [36]. However, in the light of our results a simi-
lar therapy with E2 would not have the same potentially
beneficial outcome in men.
Indeed, both men and women produce E2, although in
different amounts, which also vary depending on age.
We put forward that the observed induction in the PGR
expression mediated by E2 in the female human
myocardium facilitates the anti-proliferative effects of
progesterone on cardiac fibroblasts through the E2-
dependent increase of the responsiveness of these cells
to progesterone; hence E2 modulates remodelling in the
heart facilitating a beneficial outcome in women. Our
hypothesis is in agreement with and may explain the
observations made in human and animal studies, where
females undergo more favourable remodelling than
males. Along this line, we speculate that premenopausal
women have higher cardiac PGR levels than both post-
menopausal women and men due to higher endogenous
E2 levels, hence providing an additional explanation for
the later onset of cardiovascular disease observed gener-
ally in women.
Conclusions
In conclusion, we have shown that E2 induces the
expression of the PGR mRNA and protein in the myo-
cardium of women but not in that of men. In addition,
we have developed a hypothesis implicating this sex-
specific regulation of PGR by E2 in the development of
disease in men and women, which awaits further investi-
gation. Furthermore, our biological discovery proves the
usefulness and the relevance of the ex vivo system we
have developed for tissue culture. We anticipate that it
will allow further genomic and proteomic studies on a
high-throughput scale offering insights and advancing
our understanding of the cellular effects of stimuli and
c o m p o u n d st h a td r i v et h et i s s u er e s p o n s et od i s e a s ei n
humans.
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ECM: extracellular matrix; HBC: 2-hydroxypropyl-b-cyclodextrin; KHB: Krebs
Henseleit buffer; mRNA: messenger RNA; PBS: phosphate buffered saline;
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Figure 3 Sex-specific PGR (progesterone receptor) regulation by E2 in human cardiac tissues. (A) E2 increased the PGR gene expression
level in tissues of female individuals (n = 4, adjusted P = 0.001) but (B) the same treatment had no effect in tissues from male individuals (n =9 ,
adjusted P = 0.9). (C) E2 exposure increased the PGR protein level in tissues of female individuals (n = 4, adjusted P = 0.03). (D) On the other
hand, the same treatment with E2 revealed a decreasing trend of the PGR protein level in tissues of male individuals (n = 4, adjusted P = 0.079).
Data represent means ± standard deviation.
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